{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-080041","form_type":"8-K","ticker":"PLYX","cik":"0002075320","company_name":"Polaryx Therapeutics, Inc.","filed_at":"2026-07-21T20:30:46+00:00","discovered_at":"2026-07-21T20:31:04.271242+00:00","generated_at":"2026-07-21T20:31:18.764922+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediately","bullets":["CMO Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately.","Company states resignation will not affect clinical timelines, regulatory plans, or development strategy.","Search for successor commenced; existing leadership team will assume CMO responsibilities in interim."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-080041","json":"https://secwatch.observer/filing/0001213900-26-080041.json","markdown":"https://secwatch.observer/filing/0001213900-26-080041.md","text":"https://secwatch.observer/filing/0001213900-26-080041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/0001213900-26-080041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/ea0298434-8k_polaryx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-21T20:31:18.764922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}